Novalgin 3 ampoules

"Novalgin Ampoule each vial 2ml contains 1g metamizole sodium for injection. Novalgin Ampoule cartoon box containing 3 glass ampoules each of 2 ml & inner leaflet. "

"Dosage Age 3-11 Months (5-8kg) 0.1-0.2 ml Novalgin (equivalent to 50-100mg metamizole sodium) IM only. Dosage Age 1-3 Years(9-15kg) 0.2-0.5 ml Novalgin (equivalent to 100-250mg metamizole sodium). Dosage Age 4-6 Years (16-23kg) 0.3-0.8 ml Novalgin (equivalent to 150-400mg metamizole sodium). Dosage Age 7-9 Years (24-30kg) 0.4-1ml Novalgin (equivalent to 200-500mg metamizole sodium). Dosage Age 10-12Years (31-45kg) 0.5-1 ml Novalgin (equivalent to 250-500mg metamizole sodium). Dosage Age 13-14 Years (46-53kg) 0.8-1.8 ml (46-53kg) Novalgin (equivalent to 400-900mg metamizole sodium). Dosage Adults and young 15 Years of age< 53kg 1-2ml Novalgin (equivalent to 500-1,000mg metamizole sodium). If necessary, the single dose may be increased to 5ml (equivalent to 2500mg metamizole sodium) and daily dose is 10 ml(equivalent to 5000mg metamizole sodium)"

-Rare:Leucopenia -Very rare:Agranulocytosis, including fatal outcome, thrombocytopenia. -Not known: Aplastic anaemia, pancytopenia, including fatal outcome. -There are occasional indications that the risk of agranulocytosis may be increased when Novalgin Oblong is used for more than one week. This reaction is not dose dependant and may occur at any time during treatment. The signs are a high fever, chills, sore throat, swallowing difficulties and inflammation in the mouth, nose, throat and genital or anal area.

-In elderly patients the dose should be reduced. -In patients with impaired general health and reduced creatinine clearance, the dose should be reduced. -In patients with impaired hepatic function: repeated high doses should be avoided. -Should not be used for patients with disorders of bone marrow function (e.g. following cytostatic treatment) or diseases of the haematopoietic system. -Should not be used for patients with congenital glucose-6-phosphate dehydrogenase deficiency. -Should not be used for children below 10 years of age. -If signs of agranulocytosis or thrombocytopenia are observed, the use of Novalgin Oblong must be discontinued immediately. -Incase of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Product is to be store temperature not exceeding 30°C.

-Metamizole may lead to a reduction in serum cyclosporin levels.These must therefore be monitored if Novalgin Oblong is used concomitantly. -During concomitant use of Novalgin Oblong and chlorpromazine, severe hypothermia may occur. -Adding metamizole to methotrexate may increase the hematotoxicity of methotrexate particularly in elderly patients. Therefore, this combination should be avoided. -Metamizole may reduce the effect of acetylsalicylic acid (aspirin) on platelet aggregation, when taken concomitantly. Therefore, this combination should be used with caution in patients taking low dose aspirin for cardioprotection. -The efficacy of antihypertensive drugs and diuretics may be modified. The extent to which metamizole also leads to these interactions is unknown.

-No adequate data is available on the use of Novalgin Oblong in pregnant women. -Breast feeding should be discontinued when using metamizole and for at least 48 hours after taking the last dose of Novalgin Oblong. -Ask your physician or pharmacist before taking any medication during pregnancy or lactation.

SANOFI